病毒RNA聚合酶抑制剂AT-527治疗COVID-19,Chugai制药公司将负责日本的开发和销售

2021-02-20 Allan MedSci原创

日本Chugai制药株式会社今天宣布,它与罗氏公司达成了一项许可协议,以在日本开发和销售新型口服抗COVID-19候选药物AT-527。

日本Chugai制药株式会社今天宣布,它与罗氏公司达成了一项许可协议,以在日本开发和销售新型口服抗COVID-19候选药物AT-527。

AT-527是一种研究性的口服嘌呤核苷酸前药,已证明其对几种单链RNA病毒(包括人类黄病毒和冠状病毒)的体外和体内抗病毒活性。这种高度选择性的嘌呤核苷酸前药旨在独特地抑制病毒RNA依赖性RNA聚合酶,这是一种复制RNA病毒必不可少的酶。AT-527的抗病毒活性和安全性已在丙型肝炎患者的II期临床研究中以及在SARS-CoV2病毒的临床前体外测定中得到证实。值得注意的是,AT-527尚未在任何国家/地区获得许可或批准用于任何用途。

罗氏公司和Atea公司合作开发了AT-527。如果获得批准,Atea将在美国分销AT-527,而罗氏将负责在美国以外的全球制造和分销。根据罗氏与Chugai制药之间的许可协议,Chugai制药获得了AT-527在日本的独家开发和销售权。

全球范围内,目前正在对需要住院的中度COVID-19患者和未住院的轻度至中度COVID-19患者进行II期临床研究。预计将于2021年上半年开始一项III期临床研究,以评估AT-527对轻度或中度COVID-19患者的疗效和安全性。

Chugai总裁兼首席运营官Osamu Okuda博士说:“COVID-19尚未显示出减缓迹象,并且仍然需要新的治疗选择”。

 

原始出处:

https://www.firstwordpharma.com/node/1802295?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687388, encodeId=4285168e388a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Aug 01 03:46:51 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968023, encodeId=5fbc1968023bc, content=<a href='/topic/show?id=462c155e279' target=_blank style='color:#2F92EE;'>#RNA聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15572, encryptionId=462c155e279, topicName=RNA聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 10 01:46:51 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852610, encodeId=67f51852610c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 06 07:46:51 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955994, encodeId=725e19559940a, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Apr 03 22:46:51 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294604, encodeId=db9612946042f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591538, encodeId=f6fb1591538bc, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687388, encodeId=4285168e388a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Aug 01 03:46:51 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968023, encodeId=5fbc1968023bc, content=<a href='/topic/show?id=462c155e279' target=_blank style='color:#2F92EE;'>#RNA聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15572, encryptionId=462c155e279, topicName=RNA聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 10 01:46:51 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852610, encodeId=67f51852610c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 06 07:46:51 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955994, encodeId=725e19559940a, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Apr 03 22:46:51 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294604, encodeId=db9612946042f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591538, encodeId=f6fb1591538bc, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687388, encodeId=4285168e388a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Aug 01 03:46:51 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968023, encodeId=5fbc1968023bc, content=<a href='/topic/show?id=462c155e279' target=_blank style='color:#2F92EE;'>#RNA聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15572, encryptionId=462c155e279, topicName=RNA聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 10 01:46:51 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852610, encodeId=67f51852610c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 06 07:46:51 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955994, encodeId=725e19559940a, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Apr 03 22:46:51 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294604, encodeId=db9612946042f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591538, encodeId=f6fb1591538bc, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
    2021-11-06 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687388, encodeId=4285168e388a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Aug 01 03:46:51 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968023, encodeId=5fbc1968023bc, content=<a href='/topic/show?id=462c155e279' target=_blank style='color:#2F92EE;'>#RNA聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15572, encryptionId=462c155e279, topicName=RNA聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 10 01:46:51 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852610, encodeId=67f51852610c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 06 07:46:51 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955994, encodeId=725e19559940a, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Apr 03 22:46:51 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294604, encodeId=db9612946042f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591538, encodeId=f6fb1591538bc, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
    2021-04-03 晓辰
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687388, encodeId=4285168e388a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Aug 01 03:46:51 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968023, encodeId=5fbc1968023bc, content=<a href='/topic/show?id=462c155e279' target=_blank style='color:#2F92EE;'>#RNA聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15572, encryptionId=462c155e279, topicName=RNA聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 10 01:46:51 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852610, encodeId=67f51852610c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 06 07:46:51 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955994, encodeId=725e19559940a, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Apr 03 22:46:51 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294604, encodeId=db9612946042f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591538, encodeId=f6fb1591538bc, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1687388, encodeId=4285168e388a7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Aug 01 03:46:51 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968023, encodeId=5fbc1968023bc, content=<a href='/topic/show?id=462c155e279' target=_blank style='color:#2F92EE;'>#RNA聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15572, encryptionId=462c155e279, topicName=RNA聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sat Jul 10 01:46:51 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852610, encodeId=67f51852610c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 06 07:46:51 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955994, encodeId=725e19559940a, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Apr 03 22:46:51 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294604, encodeId=db9612946042f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591538, encodeId=f6fb1591538bc, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Mon Feb 22 10:46:51 CST 2021, time=2021-02-22, status=1, ipAttribution=)]

相关资讯

2017年5月26日Science期刊精华

图片来自Science期刊。 2017年5月29日/生物谷BIOON/---本周又有一期新的Science期刊(2017年5月26日)发布,它有哪些精彩研究呢?让小编一一道来。 1.Science:重磅!开发出延缓癌细胞生长的新方法 doi:10.1126/science.aai9372 癌症是一种非常复杂的疾病,但是它的定义是相当简单的:细胞发生异常和不受控制地生长。如今,在

Mol Cell:A型流感病毒RNA聚合酶复合体三维冷冻电镜结构揭示

1月22日,Molecular Cell 杂志在线发表了流感病毒RNA聚合酶复合体的结构和功能研究方面的研究成果。 流感病毒属负链RNA病毒,有A、B和C型三种类型。其中,A型流感病毒是具有极强的致病性和传播能力的流感病毒种类,在过去有记录的人类历史上,曾经反复暴发,造成人类社会巨大灾难。由于流感病毒的快速变异特点,可以不断产生具有抗药性、高致病性的新毒株,从而对人类

Science:揭示Enhancer对基因表达调控的新机制

8月31日,美国西北大学Feinberg医学院Ali Shilatifard课题组在Science杂志上在线发表了题为“PAF1 regulation of promoter-proximal pause release via enhancer activation”的研究论文,首次报道了转录延伸/暂停因子PAF1能够结合并且抑制enhancer的活性,从而进一步调节对应基因上RNAPII的暂停

Nature:史上详细转录因子TFIID三维结构出炉,力助揭示人类基因表达秘密

你的DNA不只是控制你眼睛的颜色和你是否卷舌。你的基因含有制造你身体所有蛋白的指令,而这些指令是你的细胞让你存活所持续需要的。但是在此之前,基因表达在分子水平上如何运行的一些关键细节一直有点神秘。在一项新的研究中,来自美国加州大学伯克利分校、劳伦斯伯克利国家实验室和西班牙国家研究委员会(CSIC)罗卡索拉诺物理化学研究所的研究人员

Cancer Cell:CX-5461抑制RNA聚合酶,激活p53治疗血液肿瘤

7月10日,Cancer Cell杂志报道了抑制RNA聚合酶可肿瘤特异性激活p53,从而有望治疗肿瘤。 核糖体RNA基因(rDNA)在RNA聚合酶催化下的转录增加是人类癌症的一个共同特点,但人们仍不清楚它是否是引发恶性表型所必须的。 本研究表明,小分子药物CX-5461(CX-5461是一种有效的小分子rRNA的合成抑制剂)可靶向rDNA转录,从而选择性地杀死体内的B淋巴瘤细胞,同时保持野生型

拓展阅读

Nature Biotechnology:工程改造RNA聚合酶,纯化mRNA生产,减少免疫刺激副产物

为了确保重复或长期给药的治疗应用过程中mRNA的高纯度,需要几个高成本和耗时的纯化步骤。这些额外的操作步骤常常导致RNA降解增加、质量下降和/或产量下降。

Small Methods:华中科技大学郭安源教授团队鉴定单个细胞外囊泡中的RNA特征

该研究首次通过高通量方法在单EV水平揭示EVs的转录组特征和异质性,刷新了人们对单个EV中RNA内容物的认识,为EV的功能研究和改造应用提供了重要基础。

Science:揭示Enhancer对基因表达调控的新机制

8月31日,美国西北大学Feinberg医学院Ali Shilatifard课题组在Science杂志上在线发表了题为“PAF1 regulation of promoter-proximal pause release via enhancer activation”的研究论文,首次报道了转录延伸/暂停因子PAF1能够结合并且抑制enhancer的活性,从而进一步调节对应基因上RNAPII的暂停

2017年5月26日Science期刊精华

图片来自Science期刊。 2017年5月29日/生物谷BIOON/---本周又有一期新的Science期刊(2017年5月26日)发布,它有哪些精彩研究呢?让小编一一道来。 1.Science:重磅!开发出延缓癌细胞生长的新方法 doi:10.1126/science.aai9372 癌症是一种非常复杂的疾病,但是它的定义是相当简单的:细胞发生异常和不受控制地生长。如今,在

Nature:史上详细转录因子TFIID三维结构出炉,力助揭示人类基因表达秘密

你的DNA不只是控制你眼睛的颜色和你是否卷舌。你的基因含有制造你身体所有蛋白的指令,而这些指令是你的细胞让你存活所持续需要的。但是在此之前,基因表达在分子水平上如何运行的一些关键细节一直有点神秘。在一项新的研究中,来自美国加州大学伯克利分校、劳伦斯伯克利国家实验室和西班牙国家研究委员会(CSIC)罗卡索拉诺物理化学研究所的研究人员

Mol Cell:A型流感病毒RNA聚合酶复合体三维冷冻电镜结构揭示

1月22日,Molecular Cell 杂志在线发表了流感病毒RNA聚合酶复合体的结构和功能研究方面的研究成果。 流感病毒属负链RNA病毒,有A、B和C型三种类型。其中,A型流感病毒是具有极强的致病性和传播能力的流感病毒种类,在过去有记录的人类历史上,曾经反复暴发,造成人类社会巨大灾难。由于流感病毒的快速变异特点,可以不断产生具有抗药性、高致病性的新毒株,从而对人类